reports
Kymera Therapeutics to Participate in Upcoming February Investor Confe...
Kymera Therapeutics to Participate in Upcoming February Investor Conferences WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events: Guggenheim Emerging Outlook: Biotech Summit 2026 in New York, NY on February 11 at 9:00 a.m. ET; andOppenheimer Virtual 36th Annual Healthcare Life Sciences Conference on February 26 at 2:00 p.m. ET. ...
EXL named a Leader in ISG Provider Lens™ Healthcare Digital Services –...
EXL named a Leader in ISG Provider Lens™ Healthcare Digital Services – US 2025 Study NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- [NASDAQ: EXLS], a global data and AI company, announced that it has been named a Leader for Payer Digital Transformation Services in the ISG Provider Lens™ Healthcare Digital Services – US 2025 study. This marks the fourth consecutive time that EXL has earned the Leader designation for Payer Digital Transformation Services. The report cites EXL’s strengths in harnessing artificial intelligence, data and cloud technology and marrying it with deep domain expert...
EXL Schedules Fourth Quarter and Full-Year 2025 Financial Results Conf...
EXL Schedules Fourth Quarter and Full-Year 2025 Financial Results Conference Call NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- ExlService Holdings, Inc. (NASDAQ: EXLS), a global data and AI company, will release financial results for the fourth quarter and full-year ended December 31, 2025, on Tuesday, February 24, 2026, after the market closes. An earnings news release, investor fact sheet and presentation will be published on the company’s investor relations website offering an overview of the financial results. The company will host a conference call at 10:00 a.m. EST the following day...
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b ...
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 WATERTOWN, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it recently initiated dosing i...
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advan...
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial expected to start in 1Q26, with data expected in 2H26 Advancing at least one new development candidate towards IND for a first-in-class, oral immunology program in 2026 Well-capitalized with $1.6 billion1 in cash and runway into 2029 Kymera to present its 2026 objecti...
EXL named a Leader in five quadrants in ISG Provider Lens™ Insurance S...
EXL named a Leader in five quadrants in ISG Provider Lens™ Insurance Services Global Report NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- [NASDAQ: EXLS], a global data and AI company, announced it has been recognized as a Leader in five quadrants in the ISG Provider Lens™ Insurance Services 2025 report. These include both service specialist capabilities, Life & Retirement and Property & Casualty, as well as the newly introduced categories for GenAI, Agentic AI and Global Capability Centers. This strong positioning highlights EXL’s broad, end-to-end impact across the insurance value chain a...
Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthca...
Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 WATERTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 13, 2026, at 9:00 a.m. PT/12:00 p.m. ET. Nello Mainolfi, PhD, Founder, President and CEO, will provide an overview of the Company’s progress and ...
Hooker Furnishings to Appoint New Independent Director with Industry E...
Hooker Furnishings to Appoint New Independent Director with Industry Expertise Enters Cooperation Agreement with GVIC Announces Retirement of Board Chair Chris Beeler at 2026 Annual Meeting Following 33 Years of Service to Hooker MARTINSVILLE, Va., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Hooker Furnishings Corporation (NASDAQ-GS: HOFT) (“Hooker” or the “Company”), a global leader in home furnishings, today announced it has entered into a cooperation agreement (the “Agreement”) with Global Value Investment Corporation (“GVIC”) under which GVIC and the Company will work together in good faith t...
EXL promotes seasoned insurance executive Raghav Jaggi
EXL promotes seasoned insurance executive Raghav Jaggi NEW YORK, Dec. 22, 2025 (GLOBE NEWSWIRE) -- [NASDAQ: EXLS], a global data and AI company, announced the promotion of Raghav Jaggi to Executive Vice President, Insurance Practice Leader, recognizing his exceptional leadership, strategic vision and more than two decades of contributions to EXL’s growth and success. Raghav joined EXL in 2003 and has since held multiple leadership roles across the organization. He was part of some early teams that helped build and scale EXL’s core business capabilities and later served as one of the com...
EXL Announces Share Repurchase of 1,551,970 Shares
EXL Announces Share Repurchase of 1,551,970 Shares NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- [NASDAQ: EXLS], a global data and AI company, announced that on December 15, 2025 it repurchased 1,551,970 shares of the Company’s common stock from Orogen Echo LLC (“Orogen”), an affiliate of The Orogen Group LLC, for an aggregate purchase price of $63,373,143, based on a purchase price per share of $40.834, which is the volume weighted average price over the 5 days prior to settlement. The shares were privately repurchased from Orogen under a Stock Purchase Agreement dated as of December 15, ...
Hooker Furnishings Completes Sale of Pulaski Furniture and Samuel Lawr...
Hooker Furnishings Completes Sale of Pulaski Furniture and Samuel Lawrence Furniture for Approximately $6.1 Million MARTINSVILLE, Va., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Hooker Furnishings Corporation (NASDAQ-GS: HOFT) (“Hooker” or the “Company”), a global leader in home furnishings, today announced it has completed the sale of the Pulaski Furniture and Samuel Lawrence Furniture casegoods brands to Magnussen Home Furnishings, Inc. for approximately $6.1 million, subject to certain final customary post-closing adjustments. “Completing this transaction marks a significant milestone in our j...
Kymera Therapeutics Announces Closing of Upsized $602 Million Public O...
Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the closing of its upsized underwritten public offering of $602.0 million of shares of its common stock. Kymera sold and issued 8,050,000 shares of its common stock, which includes 1,050,000 shares so...
EXL completes migration of LifePRO Digital Suite® platforms to AWS
EXL completes migration of LifePRO Digital Suite® platforms to AWS NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- [Nasdaq: EXLS], a global data and AI company, announced the successful migration of its platforms to Amazon Web Services (AWS). This milestone underscores EXL’s commitment to modernizing the life and annuity industry while deepening its collaboration with AWS. The migration to AWS provides EXL clients with a secure, scalable and resilient infrastructure that supports faster innovation and greater flexibility. By leveraging Amazon Bedrock and Kendra, EXL delivers innovative sol...
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-6...
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial KT-621 BROADEN2 Phase 2b AD trial ongoing, with data expected to be reported by mid-2027 and BREADTH Phase 2b trial in asthma on track to initiate in 1Q26 WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degra...
Kymera Therapeutics Announces Pricing of Upsized $602 Million Public O...
Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering WATERTOWN, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the pricing of its underwritten public offering of $602.0 million of shares of its common stock. Kymera is selling 7,000,000 shares of common stock in the offering, which are being sold at a public offering price of $86.00 per share. In addition, Kymera has granted the un...
Kymera Therapeutics Announces Proposed Public Offering
Kymera Therapeutics Announces Proposed Public Offering WATERTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it has commenced an underwritten public offering of $500.0 million of shares of its common stock. All of the shares of common stock to be sold in this offering are being offered by Kymera. In addition, Kymera intends to grant the underwriters a 30-day option to purchase up to an additional...
Kymera Therapeutics Announces Positive Results from BroADen Phase 1b C...
Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation from healthy volunteers to atopic dermatitis (AD) patients KT-621 achieved strong reductions in disease-relevant Type 2 biomarkers in blood, including TARC (median reduction of 74% in patients with baseline TARC...
Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermati...
Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025 Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025 WATERTOWN, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the BroADen Phase 1b clinical trial evaluating KT-621, its oral STAT6 degrader, in patients with moderate to severe atopic dermatitis (AD) on Monday, December 8,...
ExlService Holdings Inc: 1 director
A director at ExlService Holdings Inc sold 11,774 shares at 39.990USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
Seneca Foods Corp: 1 director
A director at Seneca Foods Corp sold 2,634 shares at 119.380USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.